Pfizer Animal Health acquires global rights to Epitopix vaccines

Pfizer Animal Health has agreed a global licensing deal with food animal vaccine specialist Epitopix for two new treatments.

The agreement will see Pfizer’s veterinary medicines division gain worldwide rights to Epitopix’s E. coli bacterial extract vaccine, as well as a conditionally-licensed conditionally licensed salmonella Newport bacterial extract treatment.

These vaccines are designed for use in the beef and dairy industries and are intended to prevent the spread of harmful infections among herds of cattle.

Epitopix general manager Jim Sandstrom stated that Pfizer Animal Health’s global reach and research expertise makes it an “ideal partner” in its efforts to address this global concern.

Juan Ramon Alaix, president of Pfizer Animal Health, added: “Pfizer Animal Health supports cattle producers’ continuing strides against harmful bacteria, often the most frequent causes of food-borne illnesses in people.”

Last month, the company agreed a deal to purchase farmed fish vaccines specialist Microtek, allowing it to enter the aquaculture healthcare therapeutics market for the first time.